Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.34 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | ESRRG | P62508 | 3/20 | 0.32 |
| ▸ | GLI1 | P08151 | 2/20 | 0.32 |
| ▸ | GLI2 | P10070 | 2/20 | 0.32 |
| ▸ | ESRRB | O95718 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297501 | 0.94 | GLI1 (0.35) | OPRM1ARRB1OPRK1ESRRGGLI1 | |
| SCHEMBL6295921 | 0.94 | OPRM1 (0.38) | OPRM1ARRB1OPRK1OPRD1 | |
| SCHEMBL6302156 | 0.89 | ESRRG (0.31) | ESRRG | |
| SCHEMBL6302376 | 0.88 | GLI1 (0.30) | GLI1GLI2 | |
| SCHEMBL6297392 | 0.88 | OPRM1 (0.34) | OPRM1ARRB1OPRK1OPRD1GLI1 | |
| SCHEMBL6297241 | 0.87 | LMNA (0.34) | OPRM1OPRK1OPRD1ESRRGESRRB | |
| SCHEMBL6302281 | 0.87 | OPRM1 (0.35) | OPRM1ARRB1OPRK1OPRD1ESRRG | |
| SCHEMBL7077392 | 0.84 | GLI1 (0.35) | OPRM1OPRK1OPRD1ESRRGGLI1 | |
| SCHEMBL6302089 | 0.84 | NPC1 (0.31) | ESRRGESRRB | |
| SCHEMBL6295654 | 0.83 | ESRRG (0.33) | ESRRGESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2003-09-11 | — | — | US | claimed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | claimed |
| US-6927217-B2 | HIV protease inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030171425-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2003-09-11 | — | — | US | disclosed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | DNPEP, PRSS1, PREP | OPRM1 3843/4885ARRB1 2697/4885OPRK1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.